MONTREAL, QUEBEC--(Marketwired - April 24, 2017) - IBEX Technologies Inc. ("IBEX" or the "Company") (TSX VENTURE:IBT) today announced that on April 21, 2017 the Company's Board of Directors granted stock options representing a total of 105,000 common shares to certain of its directors and officers.

These options were granted at an exercise price of $0.235, being the closing price on April 21, 2017, and will expire on April 21, 2027.

All options were granted pursuant to the IBEX Stock Option Plan.


IBEX manufactures and markets proteins for biomedical use through its wholly owned subsidiaries IBEX Pharmaceuticals Inc. (Montreal, QC) and Bio-Research Products, Inc. (North Liberty, IA). IBEX Pharmaceuticals also manufactures and markets a series of arthritis assays which are widely used in osteoarthritis research.

For more information, please visit the Company's website at

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information:

Paul Baehr
President & CEO
IBEX Technologies Inc.
514-344-4004 x 143